DBV will attend the EAACI Congress in Geneva from June 16 to June 20
As part of its ongoing R&D efforts, DBV Technologies will be highly represented at the European Allergy And ClinicalImmunology congress (http://www.eaaci2012.com) and present pre-clinical as well as clinical results.
-As part of clinical effort, DBV will present for the first time the detailed results of its phase Ib study completed early 2012, representing the first study showing the safety and well-tolerability of Viaskin Peanut in peanut allergic patients. The oral communication at the EAACI, “Epicutaneous immunotherapy for treating peanut allergy: results of the first double-blind placebo-controlled safety study” follows the result highlights announced onFebruary 28, 2012. This outstanding set of data has led DBV to launch a large worldwide efficacy study in adultsand children suffering from peanut allergy.
- DBV is also delighted that the EAACI selected for a late breaking oral session an abstract presented by AP-HP entitled “Six months epicutaneous immunotherapy in peanut allergy: safety and efficacy”. This communication by AP-HP will present efficacy results using Viaskin Peanut in peanut allergy for the first time. DBV Technologies will communicate the results on June 16, 2012 when the abstracts are made publicly available on the EAACI congress website.
Since its inception, DBV Technologies has developed rigorous and demanding scientific capabilities, matching the highest standards. As in previous years, several communications have been selected for presentation at the EAACI:
· “Intra-cellular absorption of the peanut protein is modulated by the size of the patch during epicutaneous immunotherapy”;
· “The crucial role of the stratum corneum superficial layers for the safety and efficacy of peanut epicutaneousimmunotherapy”;
· “Long term maintenance of Foxp3+ regulatory T cells induced by epicutaneous immunotherapy of mice sensitized to peanut” and;
· Prevention of sensitization to house dust mite or peanut by specific immunotherapy in mice allergic to milk.
DBV Technologies will communicate the detailed results on June 16, 2012 when the abstracts are made publicly available on the EAACI congress website under Scientific Publications.
